White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
Tejnaksh Healthcare Limited (539428) currently trades at ₹15.08, while our model-based Fair Value estimate is ₹6.84, 55% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹9.74 per share, and 1 of the 24 models we run sit above the ₹15.08 price.
Bear case: the Asset-Based group reads lowest at ₹0.9800, and 23 of the 24 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹4.78 (bear) to ₹9.25 (bull), the price of ₹15.08 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Health Care sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Tejnaksh Healthcare Limited reported revenue of ₹108M in FY2026 versus ₹127M in FY2022, a compound −4.0%/yr. Reported net income was ₹12.3M in FY2026, compounding −18.1%/yr from FY2022.
Key figures
Market cap ₹371M (≈ $3.9M) Micro · P/E ratio 17.7 · P/S ratio 2.02 · EPS (TTM) ₹2.06 · Net margin 11.4% · Return on assets (EBIT) 9.5% (5-year average) · Free cash flow ₹12.0M · Net debt ₹30.5M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 12% below its 52-week high and 35% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −37% fair-value upside, at −55%, 539428 screens richer than that median.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹1.30 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF
₹4.94
₹6.39
₹8.14
82
Growth DCF
₹4.97
₹6.25
₹7.71
80
Owner Earnings
₹6.73
₹8.81
₹11.31
78
All 24 models by family
DCF Models
FCF DCF
₹4.94
₹6.39
₹8.14
82
Owner Earnings
₹6.73
₹8.81
₹11.31
78
5Y Revenue Exit
₹5.24
₹7.58
₹10.48
73
5Y EBITDA Exit
₹8.43
₹13.39
₹19.06
75
5Y P/E Exit
₹6.66
₹10.16
₹13.73
71
10Y Revenue Exit
₹4.95
₹6.82
₹9.21
67
10Y EBITDA Exit
₹6.79
₹10.25
₹14.70
68
10Y P/E Exit
₹5.83
₹8.34
₹11.29
64
Earnings-Based
Graham-Dodd
₹3.40
₹9.29
₹12.19
65
Lynch FV
₹1.84
₹2.63
₹3.42
61
PEG = 1.0
₹1.84
₹2.63
₹3.42
57
EPV
₹2.77
₹3.01
₹3.21
74
Multiples
P/E Multiple
₹8.24
₹10.99
₹13.74
63
P/S Multiple
₹6.37
₹8.49
₹10.62
58
P/B Multiple
₹32.62
₹43.49
₹54.36
55
EV/EBIT
₹5.75
₹8.08
₹10.42
65
EV/EBITDA
₹10.62
₹14.57
₹18.52
67
EV/Revenue
₹3.75
₹5.89
₹8.03
53
Asset-Based
NCAV (Graham)
₹0.6500
₹0.9800
₹1.22
55
Growth DCF
Growth DCF
₹4.97
₹6.25
₹7.71
80
Rev-Margin DCF
₹5.24
₹7.61
₹10.26
73
Economic Profit
Residual Income
₹7.36
₹7.28
₹7.58
71
ROIC Compounder
₹2.77
₹3.01
₹3.21
72
Growth Earnings
Growth-Adj P/E
₹6.50
₹9.29
₹12.08
67
Open the full fair value analysis →
Overall quality
59/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability
39
How much profit the company makes from its sales and capital
Quality Growth
26
Are margins and returns getting better?
Cashflow
58
Do the profits arrive as real cash?
Financial strength
69
Debt, balance sheet and risk of trouble
Investment
82
Does it invest with discipline instead of growing at any price?
Low Volatility
26
How calm the share price moves, does not count
Price momentum
35
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high
35
Distance to the 52-week high, does not count
New shares
82
Buys back shares or issues new ones?
Open the full quality analysis →
VALUE 0: the price sits above our fair-value range.
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
10 more Healthcare Facilities stocks, each showing price versus our Fair Value estimate.
Pick a strategy and jump into the live analysis with that exact screen applied.
Is Tejnaksh Healthcare Limited (539428) overvalued or undervalued?
As of Nov 16, 2026, our model estimates a fair value of ₹6.84 versus a price of ₹15.08, about 55% lower (overvalued).
What is the fair value of 539428?
Our model-based fair value for Tejnaksh Healthcare Limited is ₹6.84 (as of Nov 16, 2026), built from audited fundamentals. The current price: ₹15.08.
What is the quality score of 539428?
Tejnaksh Healthcare Limited has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tejnaksh Healthcare Limited (539428)?
Our model-based price target is the fair value of ₹6.84 (as of Nov 16, 2026) from 24 valuation models. Cautious scenario ₹4.78, optimistic scenario ₹9.25. It is a calculation from audited fundamentals, not an analyst target.
What is the Tejnaksh Healthcare Limited stock forecast for 2026?
Our models put fair value at ₹6.84, about 55% lower versus a price of ₹15.08 (overvalued). Cautious scenario ₹4.78, optimistic scenario ₹9.25. The calculation is refreshed regularly with new filings.
What growth is priced into Tejnaksh Healthcare Limited (539428)?
For today's price to be fair in a discounted-cash-flow model, Tejnaksh Healthcare Limited would have to grow free cash flow by 19.4 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue fell 2.0 % per year. As of Nov 16, 2026.
What discount rate (WACC) does the fair value of 539428 use?
Our models discount Tejnaksh Healthcare Limited at 12.4 %: a base by market capitalisation (nano), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tejnaksh Healthcare Limited that is +19.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Tejnaksh Healthcare Limited (539428) delivered so far?
Over the past 5 years revenue at Tejnaksh Healthcare Limited shrank 2.0 % a year. The price currently implies free-cash-flow growth of +19.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tejnaksh Healthcare Limited (539428) growing?
The median revenue growth in the sector is +11.6 % a year. That is the yardstick for the growth priced into Tejnaksh Healthcare Limited (+19.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tejnaksh Healthcare Limited (539428)?
The free-cash-flow yield on the price is 3.92 %: that much free cash flow Tejnaksh Healthcare Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tejnaksh Healthcare Limited (539428)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tejnaksh Healthcare Limited it is ₹6.84 per share (as of Nov 16, 2026), against a price of ₹15.08. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Tejnaksh Healthcare Limited stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 539428 trades above its calculated fair value: price ₹15.08, fair value ₹6.84, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 539428?
No. The price is what the market pays today (₹15.08); the fair value is what the company's own numbers justify (₹6.84). For Tejnaksh Healthcare Limited the two are ₹8.24 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tejnaksh Healthcare Limited worth?
The market values Tejnaksh Healthcare Limited at about ₹371M (market capitalisation, as of Nov 16, 2026). Per share that is ₹15.08; our models calculate a fair value of ₹6.84 per share.
What do the bullish and bearish scenarios say about 539428?
Our models span a range for Tejnaksh Healthcare Limited: cautious scenario ₹4.78, base ₹6.84, optimistic ₹9.25 per share (as of Nov 16, 2026, price ₹15.08). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 539428?
Tejnaksh Healthcare Limited trades at a price-to-earnings ratio of 17.7 (as of Nov 16, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹6.84 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 49.3.
How far is 539428 from its 52-week high?
Tejnaksh Healthcare Limited trades at ₹15.08, about 12% below its 52-week high of ₹17.21 and 35% above the low of ₹11.18 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ₹6.84 is for.
Which stocks are comparable to Tejnaksh Healthcare Limited?
From the same area (Health Care) we also value N G Industries LTD, PINC, SHUKRAPHAR, 358570, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tejnaksh Healthcare Limited stock attractive at the current price?
The data as of Nov 16, 2026: price ₹15.08, calculated fair value ₹6.84 (−55%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 539428 calculated?
We run Tejnaksh Healthcare Limited through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹6.84 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Tejnaksh Healthcare Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on
is it worth investing now.
What is the share price of Tejnaksh Healthcare Limited (539428)?
The closing price on Nov 17, 2026 was ₹15.08. Our model-based fair value is ₹6.84, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tejnaksh Healthcare Limited right now?
The price sits above even our optimistic bull case (₹9.25). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹4.78 to ₹9.25) leaves room in how you read the outcome.
Key figures of Tejnaksh Healthcare Limited
How large is the market capitalisation of Tejnaksh Healthcare Limited (539428)?
The market capitalisation of Tejnaksh Healthcare Limited is ₹371M (≈ $3.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tejnaksh Healthcare Limited (539428)?
The price-to-sales ratio of Tejnaksh Healthcare Limited is 2.02 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tejnaksh Healthcare Limited (539428)?
Earnings per share at Tejnaksh Healthcare Limited are ₹2.06 (price ÷ EPS = P/E 17.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Tejnaksh Healthcare Limited (539428)?
The net margin of Tejnaksh Healthcare Limited is 11.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Tejnaksh Healthcare Limited (539428)?
On an EBIT basis the return on assets of Tejnaksh Healthcare Limited is 9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much net debt does Tejnaksh Healthcare Limited (539428) carry?
The net debt of Tejnaksh Healthcare Limited is ₹30.5M (fiscal year 2024, ≈ 2.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.